For these reasons, we selected changes in AGD and NR in male offspring of rats as main end points for our mixture experiments.
Large prospective trials using neo-adjuvant CT with or without targeted therapies must be designed taking distant relapses and overall survival as main end-points.
The trial was designed as a phase II study, with RR as the main end point.
If, after this Phase II study, the toxicity was considered to be acceptable and if the estimated response rate on the combination arm was at least as high as in the monotherapy arm, the trial would be continued as a randomised Phase III study, taking the duration of survival as the main end point.
The clinical efficacy of new drugs to treat osteoporosis must be judged in clinical trials that use the reduction of fracture risk as the main end point, rather than trials that use surrogate end points, such as changes in bone mineral density (BMD) (Chapurlat and Delmas 2006).
Overall survival was studied as the main end point.
The study followed the design of phase II studies, with RR as the main end point.
The trial was a phase II study, with PFS-6 percentage as the main end point.
Many of them were not designed to study regional nodal metastasis as the main end point but were included due to the paucity of such data in the MRI era.
However, within each year baseline and follow-up ChE tests were performed by the same laboratory, so we were able to use the degree of BuChE inhibition from baseline levels as the main end point even though absolute BuChE measurements differed by year.
